Abstract
Dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) hyperactivity has been linked to the development of a number of human malignancies. DYRK1A is the most studied family member, and the discovery of novel specific inhibitors is attracting considerable interest. The 8-cyclopropyl-2(pyridin-3-yl)thiazolo[5,4-f ]quinazolin-9(8H)-one (also called FC162) was found to be a promising inhibitor of DYRK1A and was characterized in biological experiments, by western transfer and flow cytometry on SH-SY5Y and pre-B cells. Here, the results obtained with FC162 are compared to well-characterized known DYRK1A inhibitors (e.g., Leucettine L41 and EHT1610).
Original language | English (US) |
---|---|
Article number | 185 |
Journal | Pharmaceuticals |
Volume | 12 |
Issue number | 4 |
DOIs | |
State | Published - Dec 2019 |
Keywords
- CMGC kinases
- DYRK family kinases
- Pre-B cells
- Quiescence
- SH-SY5Y-Tau-4R cells
- Thiazolo[5,4-f]quinazolin-9(8H)-one
ASJC Scopus subject areas
- Drug Discovery
- Molecular Medicine
- Pharmaceutical Science